News

Lawrence Severt, MD, PhD, discussed the history of CGRP antagonists and what atogepant can potentially bring to the market pending approval.

Researchers could not identify any risk factors for contracting COVID-19 in the population with epilepsy.

The senior director of patient management, care, and rehabilitation research at the National Multiple Sclerosis Society discussed the importance of fundraising events to further MS research.

An upcoming phase 2 trial will assess ketamine in up to 36 patients, using change in the Unified Dyskinesia Rating Scale as the primary end point of the study.

Sana Somani, MD, MBBS, vascular neurology fellow at the University of Maryland Medical Center, discussed her research into disparities in post-stroke care.

The professor of neurology and director of the Buffalo Neuroimaging Analysis Center discussed his work on the ORATORIO study.

Here's what is coming soon to NeurologyLive.

The founder and chief scientific officer of Neurolutions discussed the clinical tools that make up the IpsiHand Upper Extremity Rehabilitation System and the benefits it brings.

The trial will be the first neuroimaging study aimed at observing the impacts of rhythmic auditory stimulation on walking impairment in multiple sclerosis.

The Ralph and Luci Schey Chair and Director of the Schey Center for Cognitive Neuroimaging at Cleveland Clinic discussed his investigations into improving the MSPT.

The findings suggest that patients with dementia should be prioritized for stringent preventive measures, greater surveillance, and early intervention in COVID-19.

Neurology News Network for the week ending May 22, 2021.

The senior director of patient management, care, and rehabilitation research at the National MS Society discussed the organization’s ultimate goal of curing MS.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending May 21, 2021.

Marian LaMonte, MD, MSN, FAAN, chief of neurology at Ascension Saint Agnes, discussed her team’s efforts to improve compliance in providing stroke discharge instructions.

The associate professor and director of the Headache Medicine Fellowship Program at Thomas Jefferson University discussed the barriers to the use of preventive medicines.

The county with the highest premature stroke mortality was 20.78 times higher than that of the county with the lowest mortality. The data have raised alarms among the study authors.

"Mind Moments," a podcast from NeurologyLive, brings you an exclusive interview with Matthew B. Harms, MD.

A budget impact analysis suggested that Cala Health’s Cala Trio device can serve as a cost-saving treatment option for patients with ET.

Environmental factors such as smoking, alcohol consumption, overweight/obese status, and sun exposure were associated with an increased risk of relapsing-onset and progressive-onset MS.

The Ralph and Luci Schey Chair and Director of the Schey Center for Cognitive Neuroimaging at Cleveland Clinic discussed the importance of correcting practice effects to determine performance.

Only 4.9% of respondents in active clinical practice at the time of the survey reported not using telehealth when providing patient care services.

The director of the Center for Neurological Restoration at Cleveland Clinic discussed future ideas for the MANAGE-PD tool to furthering its benefits.

Vineet Punia, MD, MS, shared thoughts on his study from AAN 2021 which characterized generalized epilepsy in older adults and the elderly, and raised questions about its overall prevalence.

Join Ahmed Obeidat, MD, PhD; Mitchell Freedman, MD; and Suma Shah, MD, for the second program of this monthly series as they discuss the evolution of therapeutics for the treatment of multiple sclerosis.

Jason Poon, MD, neurologist at University of Utah, discussed his study on diagnostic accuracy in telestroke consultations.

The trial design was presented at the 2021 ENCALS meeting and is set to run for 48 weeks at more than 50 clinical centers.

The professor of neurology and director of the Buffalo Neuroimaging Analysis Center discussed the development of the aT2-LV biomarker.